Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDH2 | P48735 | 3/20 | 0.47 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.37 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.37 |
| ▸ | MELK | Q14680 | 1/20 | 0.34 |
| ▸ | CTSC | P53634 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.31 |
| ▸ | IGF1R | P08069 | 1/20 | 0.31 |
| ▸ | FBP1 | P09467 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10312181 | 0.89 | IDH2 (0.48) | IDH2HRH4NFE2L2MELKIGF1R | |
| SCHEMBL10312203 | 0.88 | FLT3 (0.38) | IDH2HRH4NFE2L2 | |
| SCHEMBL10312114 | 0.86 | HRH4 (0.34) | IDH2HRH4KMT2ALMNA | |
| SCHEMBL10312192 | 0.85 | IGF1R (0.46) | IDH2HRH4MEN1KMT2AIGF1R | |
| SCHEMBL16556933 | 0.82 | HRH4 (0.51) | IDH2HRH4MAPT | |
| SCHEMBL10312133 | 0.82 | NTRK1 (0.39) | IDH2HRH4NFE2L2IGF1R | |
| SCHEMBL10312234 | 0.81 | HRH4 (0.61) | IDH2HRH4CTSCMAPT | |
| SCHEMBL10312230 | 0.81 | IDH2 (0.52) | IDH2HRH4CTSCKMT2AMAPT | |
| SCHEMBL10312098 | 0.81 | IDH2 (0.37) | IDH2HRH4NFE2L2 | |
| SCHEMBL10312231 | 0.80 | HRH4 (0.49) | IDH2HRH4KMT2ALMNAMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120178758-A1 | STYRYL-TRIAZINE DERIVATIVES AND THEIR THERAPEUTICAL APPLICATIONS | CALIFORNIA CAPITAL EQUITY, LLC (US) | 2012-07-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120178758-A1 | STYRYL-TRIAZINE DERIVATIVES AND THEIR THERAPEUTICAL APPLICATIONS | STK25, STK35, SGK2 | IDH2 745/4885HRH4 2393/4885NFE2L2 1235/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.